---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-003236"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T07:20:53.505543+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Allurion amends notes/RIFAs with cash & revenue covenants, FDA/France deadlines; reports AUDACITY trial topline results

## Summary
- Omnibus Amendment imposes minimum cash balances and minimum trailing 12-month revenue tested quarterly starting Q3 2025.
- Deadlines: French marketing authorization by Dec 31, 2025; FDA US marketing authorization by June 30, 2026.
- Amendment fee: 5% fully-diluted shares to investors after $12M+ offering by Feb 15, 2025; else Series A-1 preferred redeemable Dec 31, 2026.
- RTW gets second board seat; Jason Richey appointed to board alongside Nicholas Lewin.
- Announced topline results from AUDACITY trial of Allurion Balloon; details in press release Exhibit 99.4.

## SEC filing metadata
- accession: 0001193125-25-003236
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000119312525003236/0001193125-25-003236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000119312525003236/d896057d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-003236
- JSON: https://secwatch.observer/filing/0001193125-25-003236.json
- Plain text: https://secwatch.observer/filing/0001193125-25-003236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.